Blog

Hagop Youssoufian: I’m very pleased to serve on the Clinical and Regulatory Advisory Board of AffyImmune Therapeutics

A collage photo of Hagop Youssoufian and AffyImmune Therapeutics.

Apr 14, 2024, 06:47

Hagop Youssoufian: I’m very pleased to serve on the Clinical and Regulatory Advisory Board of AffyImmune Therapeutics

Hagop Youssoufian, Youssoufian Consulting, LLC, posted on LinkedIn:

“I’m very pleased to serve on the Clinical and Regulatory Advisory Board of AffyImmune Therapeutics, which is aspiring to develop revolutionary CAR T therapies for a highly lethal form of thyroid cancer as well as lung cancer.”

View the article attached to the post.
Source: Hagop Youssoufian/LinkedIn

AffyImmune Therapeutics cancer CAR T therapies Clinical and Regulatory Advisory Board of AffyImmune Therapeutics Hagop Youssoufian highly lethal form cancer Lung cancer OncoDaily Oncology Revolutionary Therapies thyroid cancer

In Memory of Alan Rickman and His Battle with Prostate and Pancreatic Cancer

New Paper Alert: Systemic management of advanced HCC: an increasingly complex game

AC-satoreotide got FDA Orphan Drug Designation status for SCLC and MCC

Oncologist Near Me – Nazik Hammad: A Leader in Cancer Care, Medical Education, and Health Equity

Garo Armen - A Bold Call to Action: Embracing Real-Time Innovation in Pediatric Cancer